Encouragingly, a previous study novelly explores a multiepitope peptide vaccine made up of immunodominant epitopes of SYCP1 and ACRBP antigens as prophylactic melanoma vaccine, which shows good antigen-presenting ability and apparent therefore anti-cancer activity (41); the same research group also applies the co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes to treat murine triple-negative breast cancer model, which also exhibits satisfied anti-tumor efficiency (42). This evidence concerns the gene SYCP1 and neoplasm.